Please login to the form below
Roche, J&J and Novartis in hepatitis C diagnostics tie-up
Roche signs licensing agreements for Hepatitis C immunodiagnostics with J&J subsidiary Ortho-Clinical Diagnostics and Novartis
Swiss-based pharmaceutical group Roche has signed licensing agreements for Hepatitis C immunodiagnostics with J&J subsidiary Ortho-Clinical Diagnostics and Swiss-headquartered Novartis.
Roche, Ortho-Clinical and Novartis also agreed to settle all litigation related to licensed patents.
Roche will receive a worldwide royalty-bearing license under the deal, according to a Roche statement. Financial terms were not disclosed.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
